PTJ
KLDO

Paul Tudor Jones’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Paul Tudor Jones’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-44,165
Closed -$328K – 1622
2020
Q2 		$328K Buy
+44,165
New +$296K 0.02% 849

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Paul Tudor Jones's KLDO Position: Q3 2020 in Review

Paul Tudor Jones sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2020, closing a stake of 44,165 shares — an estimated $328K sold.

Paul Tudor Jones first reported a position in KLDO in Q2 2020 and held it in 1 quarter. The position peaked at $328K in Q2 2020. 56 funds tracked by Wall St. Rank hold KLDO as of Q3 2020.

  • Paul Tudor Jones reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Paul Tudor Jones sold 44,165 Kaleido Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $328K.
  • Paul Tudor Jones first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Paul Tudor Jones's Kaleido Biosciences, Inc. Common Stock position peaked at $328K in Q2 2020.
  • 56 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2020.

Based on Tudor Investment Corp's 13F filing for Q3 2020, filed 16 Nov 2020.